Spruce Biosciences Launches MPS3BStudy.com to Accelerate Rare Disease Trial Enrollment — Spruce Biosciences, Inc.

Event summary

Spruce Biosciences launched MPS3BStudy.com to facilitate enrollment in its Expanded Access Program (EAP) and TrAnsform confirmatory study for Sanfilippo Syndrome Type B (MPS IIIB).
The TA-ERT EAP aims to enroll 10 participants in the U.S., with initiation expected in Q4 2026.
The TrAnsform confirmatory study targets 14 participants, with a focus on evaluating the efficacy of TA-ERT on cognition.
MPS IIIB is an ultra-rare neurodegenerative disease with no FDA-approved therapies, affecting fewer than 1 in 200,000 people in the U.S.

The big picture

Spruce Biosciences' launch of MPS3BStudy.com underscores the critical need for targeted enrollment strategies in ultra-rare disease trials. The company's focus on MPS IIIB, a condition with no approved therapies, positions it at the forefront of a niche but high-impact segment of the biopharmaceutical industry. The strategic use of an EAP alongside a confirmatory study reflects a dual approach to both address unmet medical needs and gather pivotal data for regulatory approval.

What we're watching

Regulatory Timing: Whether the FDA's review of Spruce's biologics application will align with the planned initiation of the TrAnsform confirmatory study in Q4 2026.
Trial Execution: The pace at which Spruce can enroll participants in both the EAP and confirmatory study, given the ultra-rare nature of MPS IIIB.
Therapeutic Efficacy: How TA-ERT's mechanism of action will translate into clinical outcomes, particularly in preserving cognitive function in MPS IIIB patients.